| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_29a21d3c0e0eadee10a420216247f334
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_34d54c565ab886100f4211be39a0ceb6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_faf522b8b83eded745c73018576219ba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e5cd8f49579f2d95fdfae51a8254d338 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1138
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7088 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| filingDate |
2008-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a2fac21a0ad70b8ee51eb0b7220489aa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c4b3654ba30449af5029d6e5eced706e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc7c136cac5b48f452b21c464500428c |
| publicationDate |
2008-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2008114876-A1 |
| titleOfInvention |
A method of treating malignant mesothelioma |
| abstract |
The present invention relates to a therapeutic agent for malignant mesothelioma comprising a substance which inhibits binding of CD26 to extracellular matrix such as an siRNA targeting CD26 cDNA or an anti-CD26 antibody. The present invention relates to a method of treating malignant mesothelioma, which comprises administering to a patient the substance. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20180061226-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11273217-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022066847-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9920135-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022238978-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2015016267-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010099918-A1 |
| priorityDate |
2007-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |